Lichenoid dermatitis induced by abemaciclib in a patient with HR+/HER2- breast cancer
https://doi.org/10.4081/dr.2024.10144
Accepted: 17 November 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Cyclin-dependent kinase (CDK) 4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, are widely used in combination with endocrine therapy for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Despite their efficacy, these drugs are associated with a range of adverse events, including dermatologic toxicities. This case report presents a rare instance of lichenoid dermatitis in a 48-year-old woman following treatment with abemaciclib. The patient developed erythematous, edematous plaques and papules on her hands and forearms, which resolved after discontinuation of the drug and treatment with topical corticosteroids. This report highlights the need for awareness of cutaneous side effects associated with CDK4/6 inhibitors, particularly abemaciclib.
Peng TR, Chen JH, Wu TW. Efficacy and safety of cyclin-dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real-world experience. Thorac Cancer 2023;14. DOI: https://doi.org/10.1111/1759-7714.15090
Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 2020;38:3987–98. DOI: https://doi.org/10.1200/JCO.20.02514
Yang L, Xue J, Yang Z, et al. Side effects of CDK4/6 inhibitors in the treatment of HR+/HER2- advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med 2021;10:5590-9. DOI: https://doi.org/10.21037/apm-21-1096
Silvestri M, Cristaudo A, Morrone A, et al. Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin Dependent Kinase 4/6 Inhibitors: A Systematic Review. Drug Saf 2021;44:725-32. DOI: https://doi.org/10.1007/s40264-021-01071-1
Raschi E, Fusaroli M, La Placa M, et al. Skin toxicities with cyclin-dependent kinase 4/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system. Am J Clin Dermatol 2022;23:247–55. DOI: https://doi.org/10.1007/s40257-021-00645-0
Sibaud V, Sollena P. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice. Ann Dermatol Venereol. 2023;150:208-12. DOI: https://doi.org/10.1016/j.annder.2022.11.013
Mariano M, Donati P, Cameli N, et al. Ribociclib-Induced Erythema Dyschromicum Perstans (Ashy Dermatosis)-Like Pigmentation in a Metastatic Breast Cancer Patient. J Breast Cancer 2021;24:117-21. DOI: https://doi.org/10.4048/jbc.2021.24.e1
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
